Table 2. Multivariate Cox proportional hazard regression analyses in the prediction of PSA-progression free survival (PFS), C/R-PFS and overall survival (OS) in mCRPC patients.
| Variables | PSA-PFS | C/R-PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
| Age | |||||||||
| ≤ 65.0 | Ref | Ref | Ref | ||||||
| > 65.0 | 0.76 | 0.46-1.28 | 0.306 | 0.91 | 0.54-1.53 | 0.715 | 0.79 | 0.45-1.39 | 0.420 |
| PSA nadir after ADT | |||||||||
| ≤ 1.0 | Ref | Ref | Ref | ||||||
| > 1.0 | 1.13 | 0.68-1.88 | 0.635 | 0.97 | 0.59-1.61 | 0.920 | 0.98 | 0.55-1.72 | 0.934 |
| Gleason score | |||||||||
| 7 | Ref | Ref | Ref | ||||||
| 8-10 | 0.56 | 0.27-1.17 | 0.124 | 0.63 | 0.30-1.32 | 0.221 | 1.08 | 0.46-2.53 | 0.863 |
| Metastatic volume | |||||||||
| Low | Ref | Ref | Ref | ||||||
| High | 1.57 | 0.89-2.78 | 0.122 | 2.31 | 1.32-4.04 | 0.003 | 2.88 | 1.44-5.76 | 0.003 |
| ERG | |||||||||
| Negative | Ref | Ref | Ref | ||||||
| Positive | 6.00 | 2.96-12.16 | < 0.001 | 5.50 | 2.68-11.29 | < 0.001 | 3.31 | 1.66-6.64 | 0.001 |
| SOX9 | |||||||||
| Negative | Ref | Ref | Ref | ||||||
| Positive | 2.75 | 1.19-6.32 | 0.018 | 2.44 | 1.12-5.30 | 0.025 | 4.30 | 1.02-18.16 | 0.047 |
PSA-PFS, prostate specific antigen progression-free survival; C/R-PFS, clinical/radiologic progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ADT, androgen deprivation therapy.